All In Biotech

Drug Trial Radar · NCT06844214

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1

A Phase 1/Phase 2 Open-label Single Arm Study With Dose Escalation (Part A), and Dose Expansion (Part B) Parts to Evaluate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants 10 to 55 Years Old With Non-congenital Myotonic Dystrophy Type 1

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jul 23, 2025

Primary completion

Feb 28, 2029

Study completion Apr 27, 2032

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 55 years old with non-congenital myotonic dystrophy (DM) type 1 (DM1). The purpose of this study is to evaluate the safety and efficacy of SAR446268 in knocking down dystrophia myotonica protein kinase (DMPK) messenger ribonucleic acid (mRNA) levels and improving neuromuscular function in DM1 participants receiving a single intravenous (IV) administration of SAR446268. The study consists of a dose escalation part (Part A) during which single ascending doses of SAR446268 will be evaluated in 3 distinct cohorts and an optional fourth dose cohort. Once a safe and effective dose is identified, additional participants will be treated in Part B, the dose expansion phase of the study. The study duration will be 112 weeks (approximately 2 years) for each participant in Parts A and B respectively and includes an optional pre-screening period, approximately 8-week screening phase and a 104-week follow-up period post-SAR446268 administration.

Conditions

  • Myotonic Dystrophy

Interventions

  • SAR446268Biological

    Pharmaceutical form: Solution for infusion; Route of administration: IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and Part B: Incidence of treatment-emergent adverse events (TEAEs) following SAR446268 administrationTime frame: Baseline to Week 52
  2. Part B: Proportion of participants with at least 40% DMPK mRNA knockdown in muscle biopsy at Weeks 12 and 52 following SAR446268 administrationTime frame: Weeks 12 and 52

Locations

10 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Florida, 2004 Mowry Road - Site Number: 8400005

    Gainesville, Florida · Recruiting

  • University of South Florida - Neuromuscular Research, 13330 USF Laurel Drive - Site Number: 8400001

    Tampa, Florida · Recruiting

  • Columbia University Medical Center - Neurological Institute, 710 W. 168th, 2nd floor, suite 204 - Site Number : 8400003

    New York, New York · Recruiting

  • Penn Medicine: University of Pennsylvania Health System- Site Number : 8400009

    Philadelphia, Pennsylvania · Recruiting

  • Virginia Commonwealth University Medical Center- Site Number : 8400006

    Richmond, Virginia · Recruiting

  • Hospital Italiano de Buenos Aires, Juan Domingo Peron 4190 - Site Number: 0320001

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0360001

    Brisbane, Queensland, Australia · Recruiting

  • The Montreal Neurological Institute and Hospital, 3801 rue University - Site Number: 1240001

    Montreal, Quebec, Canada · Recruiting

  • Investigational Site Number : 3760002

    Ramat Gan, Israel · Recruiting

  • Investigational Site Number : 8260002

    Newcastle upon Tyne, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.